Proscia Announces Update to AI-enabled Cloud-based Workflow Solution for Pathologists

July 24, 2024 — Proscia, a developer of artificial intelligence (AI)-enabled digital pathology solutions for precision medicine, has introduced the next version of Concentriq AP. The release includes new functionality that advances the impact of AI in shaping pathologists’ understanding of four of the top five most common cancers worldwide. Concentriq AP is a cloud-based workflow solution that helps even the largest global laboratory networks achieve the confidence and efficiency gains enabled by digital pathology, according to a written statement released by the Phil., PA-based software company.

The company reports that the major update delivers the industry’s first multi-AI workflows, which simultaneously display results from more than one application in Proscia’s precision medicine AI portfolio on the same image. Pathologists can tap into the comprehensive picture these applications collectively provide in a single pane of glass, moving beyond analyzing insights from individual solutions in isolation. In addition, applications for breast, colon, gastric, lung, and prostate images are immediately available, and Proscia will address additional tissue types and use cases as it expands its portfolio with other leading third-party solutions.  

“As AI continues to demonstrate benefits, laboratories are increasingly seeking to leverage a variety of applications,” said Derek C. Welch, M.D., Chief Medical Officer and Executive Vice-President at PathGroup, adding, “Concentriq AP now enables them to realize the collective value of a broad AI portfolio while providing a robust solution for their routine operations.”

The new release of Concentriq AP also offers features and functionality including: the ability to view and ingest DICOM images, laying the foundation for realizing the IT efficiencies and enhanced interoperability this standard delivers; API updates that enable the seamless integration of additional third-party and customer-built AI applications into Concentriq AP’s multi-AI workflows; full support for 13 languages aligned to Proscia’s growing global customer base; and performance, scalability, and usability enhancements that optimize Concentriq AP as laboratories look to achieve 100% digitization.

Concentriq AP is for research use only. Not for use in diagnostic procedures.

“We built the new version of Concentriq AP working closely with our growing customer base to realize our vision for pathology’s precision medicine future,” said Sowmya Ballakur, Proscia’s Senior Vice President of Product. Ballakur added, “It gives them the features they need to scale their use of AI-enabled pathology and capitalize on the latest innovations that shape our understanding of disease.” 

Today’s news comes on the heels of a series of announcements from Proscia. The company noted it recently released findings from a study conducted with Quest Diagnostics, a leading provider of diagnostic information services, on the impact of its AI-enabled workflows. It also announced a partnership with Nucleai through which it will be making Nucleai’s AI predictive biomarkers available as part of its precision medicine AI portfolio. Additionally, the company’s written statement noted that Proscia has grown its clinical customer base by more than 100% in the past year.  

The software company is accelerating the transformation to digital pathology to change the way diseases like cancer are understood. Proscia contends that its Concentriq enterprise pathology platform and powerful AI applications are “advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision medicine.” It further reports that leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software.

More information: www.proscia.com